Educate Why Aducanumab Isn't a Miracle for Alzheimer's
August 2021
You'll hear controversy about aducanumab (Aduhelm), the first new med for Alzheimer's disease in almost 20 years.
It's a monoclonal antibody given as an IV infusion every 4 weeks.
Aducanumab is only approved for Alzheimer's patients with mild cognitive impairment or mild dementia. It's NOT for more severe disease or other types of dementia...there are no data in these patients.
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote